SOT stands for Supportive Oligonucleotide Therapy. An oligonucleotide is a short synthetic strand of nucleic acid — a tiny molecule designed in a laboratory to match and bind to a very specific sequence in a pathogen's genetic code. When it binds, it blocks the pathogen from producing a protein essential for its survival or replication. The pathogen cannot adapt fast enough. It gradually loses the ability to reproduce, and its population declines.
This technology is not experimental in medicine broadly — FDA-approved antisense drugs are already used for genetic diseases and one virus. Its application to Lyme disease is newer and still emerging. But the foundational science is established.
How SOT is made and how it works
A blood sample is taken and sent to RGCC Laboratories in Greece — the facility that processes SOT internationally. Using PCR and molecular biology, the lab identifies which pathogens are present and characterises the specific genetic strain of Borrelia active in that patient. This matters because different strains have slight genetic variations, and the SOT molecule must match the exact sequence of the strain being treated.
The laboratory designs a short siRNA (small interfering RNA) or antisense oligonucleotide that binds precisely to a critical section of Borrelia's DNA — a sequence that controls an essential function such as cell wall synthesis or replication. Newer protocols use QRE-strain (Quasispecies Resistant Engineered strain) technology to account for minor genetic variations within the same pathogen species, increasing the likelihood that the molecule remains effective across strain variants.
The prepared SOT solution is returned to the treating clinic and administered as a single intravenous infusion — typically taking 5–10 minutes for the SOT itself, within a 90–120 minute clinical appointment that includes saline, an antihistamine, and a short period of monitoring afterward. No hospitalisation is required.
This is what makes SOT different from every other therapy in this section. The oligonucleotide molecules are engineered to evade the immune system and resist degradation by the body's RNA-clearing enzymes. They circulate continuously, crossing the blood-brain barrier, and work 24 hours a day for up to six months after a single infusion. They find Borrelia wherever it is — in tissue, in the brain, in biofilm — and bind to it without any further input from the patient.
At 4–6 months post-infusion, the patient is retested by PCR. If Borrelia DNA is still detectable, a second infusion can be administered — up to three per year. With each round, a new SOT molecule may be designed if the pathogen profile has changed. If co-infections (Bartonella, Babesia, EBV) are also present, separate SOT infusions targeting each are required.
What the evidence shows
The first peer-reviewed clinical study of SOT for Lyme disease. 115 patients with Borrelia burgdorferi, EBV, or HSV infections received SOT infusions. PCR testing before and after infusion was used to measure the effect on pathogen DNA levels in blood. The study found measurable reductions in Borrelia burgdorferi DNA copy numbers following one or two infusions in Lyme patients. The authors describe SOT as "a potential treatment for viral infections and Lyme disease" and call for further study. Published in Infectious Disease Reports, a peer-reviewed journal. PMID: 36412742.
This is a small pilot study, not a randomised controlled trial. But it is clinical data from human patients, published in a peer-reviewed journal, with PCR-confirmed outcomes. In the landscape of alternative Lyme therapies, that is a meaningful distinction.
Antisense oligonucleotide therapy is not fringe science. The first FDA-approved antisense drug — fomivirsen (Vitravene) — was approved in 1998 for CMV retinitis. Since then, FDA-approved antisense drugs have been developed for spinal muscular atrophy, Duchenne muscular dystrophy, and several other conditions. The mRNA technology used in COVID-19 vaccines is a cousin of the same gene-medicine field. SOT for infectious disease is an emerging application of an established scientific class, not a leap into the unknown.
What makes SOT different from everything else
No daily pills, no repeated sessions, no compliance required. One treatment works continuously for half a year.
Designed for the exact strain in your body, not a generic compound. No other treatment in this section is personalised to this degree.
Penetrates the CNS — where antibiotics often cannot reach in sufficient concentration and where Borrelia frequently persists in neurological Lyme.
Acts directly at the genetic level. Does not require a functional immune system to work — relevant for Lyme patients with significant immune suppression.
What SOT cannot do — and what to watch for
- One infusion per co-infection. SOT targets one pathogen per infusion. If you have Borrelia, Bartonella, and Babesia simultaneously, each requires its own separately designed molecule and its own infusion. This multiplies both cost and time-to-treatment.
- Herxheimer reactions. As Borrelia is progressively silenced over weeks and months, bacterial die-off triggers detox reactions. Most patients experience an initial worsening — fatigue, aches, cognitive symptoms — that gradually resolves. The reaction is typically slower-building than with antibiotics (days to weeks, not immediate), reflecting the gradual nature of the mechanism.
- Cost. A single SOT infusion for one pathogen typically costs €1,500–€5,000 depending on the clinic and country. Multiple co-infections requiring multiple infusions can bring total cost significantly higher. Not covered by public health insurance anywhere.
- Not FDA-approved for Lyme. SOT is used entirely off-label for Lyme disease in all countries. The clinical data is preliminary. Patients proceed without the regulatory framework that would apply to an approved treatment.
- Limited availability. RGCC-partnered clinics that offer SOT exist in Poland and across Europe, but they are not common. Finding a clinic with legitimate RGCC certification matters — some clinics claim to offer SOT without the RGCC laboratory process behind it.
- Gradual effect. SOT does not produce immediate relief. The mechanism is gradual suppression of replication over months. Patients expecting rapid results will be disappointed and may discontinue before the therapy has had time to work.
Other approaches in this section
Low dose naltrexone works at a completely different level — not targeting the bacteria directly, but resetting the immune dysregulation that Lyme leaves behind. For patients whose bacterial load is managed but symptoms persist, LDN may be the next question worth asking.
Healing mentality checkpoint
SOT's elegance as a concept can make it feel like a solution — finally, something precise, something that works at the right level. The research is genuinely promising. But "promising" and "proven" are not the same word. Go into this with appropriate scepticism alongside appropriate curiosity. And make sure the cost is something you can absorb without putting your financial stability at risk.
Read about healing mentality →Sources & further reading
- Apostolou P. et al. — Supportive Oligonucleotide Therapy (SOT) as a potential treatment for viral infections and Lyme disease: preliminary results, Infectious Disease Reports (2022) — PubMed PMID: 36412742
- LymeDisease.org — SOT therapy for Lyme: experimental, expensive, and full of potential (2025)
- LymeDisease.org — Targeting Lyme at the genetic level: SOT's emerging role (2025)
- Project Lyme — Supportive Oligonucleotide Therapy for Lyme overview
- RGCC Laboratories — rgcc-genlab.com
- FDA — antisense oligonucleotide approved drugs: historical context
Last updated: March 2026